10 recruiting. 10 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 10 |
| Phase 3 | 2 | Recruiting 2 |
Follow Eczema: new trials by email Literature Review of Eczema trials Research Report on Eczema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis Camoteskimab, Placebo - Atopic Dermatitis, Atopic | Phase 2 | Recruiting | Apollo Therapeutics Ltd | 280 | 2026-05-28 | 2026-08-28 |
| Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD Soquelitinib, Placebo - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Recruiting | Corvus Pharmaceuticals, Inc. | 200 | 2026-02-01 | 2026-03-05 |
| A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema PF-08049820, Placebo - Atopic Dermatitis, Eczema, Atopic | Phase 2 | Recruiting | Pfizer | 165 | 2025-11-20 | 2026-10-13 |
| A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) GX-03, Vehicle - Eczema Atopic Dermatitis, Eczema | Phase 2 / Phase 3 | Recruiting | Turn Therapeutics | 190 | 2025-07-11 | 2026-09-04 |
| A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis IMG-007, Placebo - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Recruiting | Inmagene LLC | 405 | 2025-06-17 | 2026-08-12 |
| Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis GHZ339, Placebo - Atopic Dermatitis | Phase 2 | Recruiting | Novartis Pharmaceuticals | 224 | 2025-05-16 | 2026-09-28 |
| Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. zabalafin - Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema | Phase 2 | Recruiting | Alphyn Biologics | 72 | 2025-03-25 | 2025-08-01 |
| Herbal Ointment in Treating Atopic Dermatitis Topically herbal ointment, Placebo - Atopic Dermatitis, Atopic Dermatitis (AD) | Phase 2 / Phase 3 | Recruiting | En Chu Kong Hospital | 66 | 2025-03-01 | 2025-02-27 |
| Cardamom and Topical Roseomonas in Atopic Dermatitis Roseomonas mucosa (RSM2015) and Cardamom seeds, Placebo (sucrose) - Atopic Dermatitis, Eczema | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 120 | 2024-10-09 | 2026-10-30 |
| Effects of Treatments on Atopic Dermatitis Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline - Eczema, Dermatitis | Phase 2 | Recruiting | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 130 | 2012-09-18 | 2026-10-29 |
Dermatitis, Atopic (10) · Dermatitis (5) · Skin Diseases (4) · Skin Diseases, Genetic (2) · Exanthema (1) · Immune System Diseases (1) · Pruritus (1) · Skin Diseases, Eczematous (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10) · Hypersensitivity (10) · Hypersensitivity, Immediate (10) · Skin and Connective Tissue Diseases (10) · Immune System Diseases (9) · Skin Diseases, Eczematous (9) · Skin Diseases, Genetic (8) · Skin Diseases (6) · Dermatitis (5) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Skin Manifestations (1)
Cephalexin (1) · Doxycycline (1) · Sodium Hypochlorite (1) · Sucrose (1) · Sulfamethoxazole (1) · Trimethoprim (1)
Alphyn Biologics (1) · Apollo Therapeutics Ltd (1) · Corvus Pharmaceuticals, Inc. (1) · En Chu Kong Hospital (1) · Inmagene LLC (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · Turn Therapeutics (1)
United States (8) · Canada (4) · Czechia (3) · Poland (3) · Australia (2) · Bulgaria (2) · China (2) · France (2) · Germany (2) · Hungary (2) · Japan (2) · Spain (2) · Taiwan (2) · Argentina (1) · Italy (1)
Gary Pekoe, PhD (1) · Heidi H Kong, M.D. (1) · Ian A Myles, M.D. (1) · Isin Sinem Bagci, MD (1)
2025 (1)